Spanish Registry of Childhood Tumours (RETI-SEHOP), University of Valencia, Valencia, Spain; Paediatric Oncohematology Unit, Hospital La Fe; and Department of Paediatrics, University of Valencia, Valencia, Spain.
Spanish Registry of Childhood Tumours (RETI-SEHOP), University of Valencia, Valencia, Spain.
Cancer Epidemiol. 2022 Jun;78:102145. doi: 10.1016/j.canep.2022.102145. Epub 2022 Mar 25.
Linkage between clinical databases and population-based cancer registries may serve to evaluate European Reference Networks' (ERNs) activity, by monitoring the proportion of patients benefiting from these and their impact on survival at a population level. To test this, a study targeting neuroblastoma (Nb) was conducted in Spain by the European Joint Action on Rare Cancers.
Subjects: Nb cases, incident 1999-2017, aged < 15 years. Linkage included: Spanish Neuroblastoma Clinical Database (NbCDB) (1217 cases); Spanish Registry of Childhood Tumours (RETI) (1514 cases); and 10 regional population-based registries (RPBCRs) which cover 33% of the childhood population (332 cases). Linkage was semiautomatic. We estimated completeness, incidence, contribution, deficit, and 5-year survival in the databases and specific subsets.
National completeness estimates for RETI and NbCDB were 91% and 72% respectively, using the Spanish RPBCRs on International Incidence of Childhood Cancer (https://iicc.iarc.fr/) as reference. RPBCRs' specific contribution was 1.6%. Linkage required manual crossover in 54% of the semiautomatic matches. Five-year survival was 74% (0-14 years) and 90% (0-18 months).
All three databases were incomplete as regards Spain as a whole and should therefore be combined to achieve full childhood cancer registration. A unique personal patient identifier could facilitate such linkage. Most children have access to Nb clinical trials. Consolidated interconnections between the national registry and clinical registries (including ERNs and paediatric oncology clinical groups) should be established to evaluate outcomes.
通过监测从这些网络中受益的患者比例及其对人群水平生存率的影响,将临床数据库与基于人群的癌症登记处相联系,可用于评估欧洲参考网络(ERNs)的活动。为此,一项针对神经母细胞瘤(Nb)的研究在西班牙由罕见癌症欧洲联合行动进行。
研究对象:1999 年至 2017 年期间发病、年龄<15 岁的 Nb 病例。联系包括:西班牙神经母细胞瘤临床数据库(NbCDB)(1217 例);西班牙儿童肿瘤登记处(RETI)(1514 例);以及覆盖 33%儿童人口的 10 个地区基于人群的登记处(RPBCRs)(332 例)。联系是半自动的。我们在数据库和特定亚组中估计了完整性、发病率、贡献、缺陷和 5 年生存率。
使用西班牙 RPBCRs 作为参考,基于国际儿童癌症发病率(https://iicc.iarc.fr/),RETI 和 NbCDB 的全国完整性估计分别为 91%和 72%。RPBCRs 的特定贡献为 1.6%。在半自动匹配中,有 54%需要手动交叉核对。5 年生存率为 74%(0-14 岁)和 90%(0-18 个月)。
就整个西班牙而言,所有三个数据库都不完整,因此应合并以实现儿童癌症的全面登记。唯一的个人患者标识符可以促进这种联系。大多数儿童都可以参加 Nb 临床试验。应建立国家登记处与临床登记处(包括 ERNs 和儿科肿瘤临床组)之间的综合连接,以评估结果。